Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial.

Bravaccini S, Bronte G, Scarpi E, Ravaioli S, Maltoni R, Mangia A, Tumedei MM, Puccetti M, Serra P, Gianni L, Amaducci L, Biglia N, Bounous V, Paradiso AV, Silvestrini R, Amadori D, Rocca A.

Ther Adv Med Oncol. 2020 Feb 27;12:1758835919888999. doi: 10.1177/1758835919888999. eCollection 2020.

2.

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663.

Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL, Romeo A.

Cancers (Basel). 2020 Jan 10;12(1). pii: E178. doi: 10.3390/cancers12010178.

3.

Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients.

Schirosi L, Saponaro C, Giotta F, Popescu O, Pastena MI, Scarpi E, Mangia A.

Transl Oncol. 2020 Feb;13(2):186-192. doi: 10.1016/j.tranon.2019.10.020. Epub 2019 Dec 19.

4.

The challenge of prognostication in palliative radiotherapy: the way forward is shared decision-making.

Rossi R, Scarpi E, Dall'Agata M, Tontini L, Pieri M, Micheletti S, Romeo A, Ricci M, Pallotti MC, Maltoni M.

Support Care Cancer. 2020 Apr;28(4):1545-1546. doi: 10.1007/s00520-019-05157-6. Epub 2019 Nov 22. No abstract available.

PMID:
31758320
5.

Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer.

De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, Alvarez RH, Ueno NT, Cristofanilli M, Reuben JM.

Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065. doi: 10.1177/1758835919866065. eCollection 2019.

6.

Independent Negative Prognostic Role of TCF1 Expression within the Wnt/β-Catenin Signaling Pathway in Primary Breast Cancer Patients.

Saponaro C, Scarpi E, Zito FA, Giotta F, Silvestris N, Mangia A.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1035. doi: 10.3390/cancers11071035.

7.

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U.

Prostate. 2019 Aug;79(11):1211-1220. doi: 10.1002/pros.23804.

PMID:
31251826
8.

Special Issue on Basic and Translational Research in Colorectal Cancer.

Ulivi P, Scarpi E, Passardi A.

Int J Mol Sci. 2019 Jun 25;20(12). pii: E3095. doi: 10.3390/ijms20123095.

9.

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up.

Parisi E, Genestreti G, Sarnelli A, Ghigi G, Arpa D, Burgio MA, Gavelli G, Rossi A, Scarpi E, Monti M, Tesei A, Polico R, Romeo A.

Radiat Oncol. 2019 Jun 24;14(1):112. doi: 10.1186/s13014-019-1317-x.

10.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.

Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, Schepisi G, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U.

Eur J Cancer. 2019 Jul;116:158-168. doi: 10.1016/j.ejca.2019.05.007. Epub 2019 Jun 11.

PMID:
31200322
11.

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study.

Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, Passardi A.

Cancer Manag Res. 2019 May 10;11:4357-4369. doi: 10.2147/CMAR.S198651. eCollection 2019. Erratum in: Cancer Manag Res. 2020 Jan 23;12:541.

12.

Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors.

Giusti R, Scarpi E, Cannita K, Silva RR, Filetti M, Mazzotta M, Ficorella C, Botticelli A, Maltoni M, Marchetti P, Porzio G, Verna L.

Support Care Cancer. 2020 Mar;28(3):1051-1058. doi: 10.1007/s00520-019-04905-y. Epub 2019 Jun 8.

PMID:
31177390
13.

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Bronte G, Rocca A, Ravaioli S, Scarpi E, Bonafè M, Puccetti M, Maltoni R, Andreis D, Martinelli G, Bravaccini S.

J Oncol. 2019 Apr 14;2019:1393505. doi: 10.1155/2019/1393505. eCollection 2019.

14.

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study.

Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL, Romeo A.

Cancers (Basel). 2019 May 13;11(5). pii: E663. doi: 10.3390/cancers11050663. Erratum in: Cancers (Basel). 2020 Jan 10;12(1):.

15.

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer.

Canale M, Marisi G, Passardi A, Scarpi E, Ulivi P.

J Vis Exp. 2019 Mar 14;(145). doi: 10.3791/58615.

PMID:
30933052
16.

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.

De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A.

Int J Mol Sci. 2019 Mar 26;20(6). pii: E1503. doi: 10.3390/ijms20061503.

17.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.

Eur Urol. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26.

18.

Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients.

Catacchio I, Silvestris N, Scarpi E, Schirosi L, Scattone A, Mangia A.

Transl Oncol. 2019 Mar;12(3):585-595. doi: 10.1016/j.tranon.2018.12.005. Epub 2019 Jan 22.

19.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.

Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U.

BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1.

20.

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi: 10.2147/CMAR.S181570. eCollection 2018.

21.

Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib.

Casadei Gardini A, Scarpi E, Foschi FG, Marisi G, Maltoni M, Frassineti GL.

Clin Res Hepatol Gastroenterol. 2019 Oct;43(5):e76-e78. doi: 10.1016/j.clinre.2018.11.005. Epub 2018 Dec 5. No abstract available.

PMID:
30528062
22.

Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes.

Scarpi E, Dall'Agata M, Zagonel V, Gamucci T, Bertè R, Sansoni E, Amaducci E, Broglia CM, Alquati S, Garetto F, Schiavon S, Quadrini S, Orlandi E, Casadei Gardini A, Ruscelli S, Ferrari D, Pino MS, Bortolussi R, Negri F, Stragliotto S, Narducci F, Valgiusti M, Farolfi A, Nanni O, Rossi R, Maltoni M; Early Palliative Care Italian Study Group (EPCISG).

Support Care Cancer. 2019 Jul;27(7):2425-2434. doi: 10.1007/s00520-018-4517-2. Epub 2018 Oct 24.

PMID:
30357555
23.

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.

Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U.

Sci Rep. 2018 Oct 18;8(1):15442. doi: 10.1038/s41598-018-33774-4.

24.

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.

Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G, Valgiusti M, Passardi A, Frassineti GL, Scarpi E.

Onco Targets Ther. 2018 Oct 5;11:6555-6567. doi: 10.2147/OTT.S170836. eCollection 2018.

25.

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial.

Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A.

Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi: 10.2147/OTT.S166614. eCollection 2018.

26.

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.

Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A.

Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi: 10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. Review.

PMID:
30097237
27.

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).

Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, Zavallone L, Ventriglia J, Franzese E, Loizzi V, Giardina D, Pigozzi E, Cioffi R, Pignata S, Giorda G, De Giorgi U.

Target Oncol. 2018 Aug;13(4):469-479. doi: 10.1007/s11523-018-0574-1.

PMID:
29948780
28.

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?

Bronte G, Bravaccini S, Ravaioli S, Puccetti M, Scarpi E, Andreis D, Tumedei MM, Sarti S, Cecconetto L, Pietri E, De Simone V, Maltoni R, Bonafè M, Amadori D, Rocca A.

Transl Oncol. 2018 Aug;11(4):950-956. doi: 10.1016/j.tranon.2018.05.006. Epub 2018 Jun 18.

29.

Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Molinari C, Frassineti G, Amadori D, Ulivi P.

Ann Oncol. 2018 Jun;29 Suppl 5:v59. doi: 10.1093/annonc/mdy151.210. Epub 2020 Jan 7. No abstract available.

30.

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.

Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M.

Tumori. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9.

PMID:
29739298
31.

NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.

Saponaro C, Vagheggini A, Scarpi E, Centonze M, Catacchio I, Popescu O, Pastena MI, Giotta F, Silvestris N, Mangia A.

J Exp Clin Cancer Res. 2018 May 2;37(1):96. doi: 10.1186/s13046-018-0766-7.

32.

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?

Bravaccini S, Ravaioli S, Amadori D, Scarpi E, Puccetti M, Rocca A, Tumedei MM, Masalu N, Kahima J, Pangan A, Faustine L, Farolfi A, Maltoni R, Bonafè M, Serra P, Bronte G.

Front Endocrinol (Lausanne). 2018 Mar 29;9:137. doi: 10.3389/fendo.2018.00137. eCollection 2018.

33.

An aggressive early gastric cancer: Kodama's PenA type.

Morgagni P, Solaini L, Saragoni L, Bencivenga M, Fumagalli Romario U, Graziosi L, Marino E, Marrelli D, Rausei S, Rosa F, Scarpi E, Tomezzoli A, Tringali D, Vindigni C, Vittimberga G, Roviello F; GIRCG.

Eur J Surg Oncol. 2018 Aug;44(8):1186-1190. doi: 10.1016/j.ejso.2018.03.016. Epub 2018 Mar 27.

PMID:
29628438
34.

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, Andreis D, Maltoni R, Sarti S, Cecconetto L, Fedeli A, Pietri E, De Simone V, Asioli S, Amadori D, Bravaccini S.

BMC Cancer. 2018 Mar 27;18(1):348. doi: 10.1186/s12885-018-4239-3.

35.

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis.

Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, Paganelli G.

Sci Rep. 2018 Mar 9;8(1):4254. doi: 10.1038/s41598-018-22594-1.

36.

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.

Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A, Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A.

Eur Radiol. 2018 Jul;28(7):2969-2978. doi: 10.1007/s00330-017-5254-5. Epub 2018 Feb 7.

PMID:
29417252
37.

Association among metabolic syndrome, inflammation, and survival in prostate cancer.

Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Lolli C, Kinspergher S, Schepisi G, Santoni M, Santini D, Fratino L, Burgio SL, Salvi S, Menna C, De Giorgi U.

Urol Oncol. 2018 May;36(5):240.e1-240.e11. doi: 10.1016/j.urolonc.2018.01.007. Epub 2018 Mar 2.

PMID:
29402534
38.

Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.

Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, Scarpi E, Di Mauro F, Rossi A, Matteucci F, Paganelli G.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):923-930. doi: 10.1007/s00259-017-3925-8. Epub 2018 Feb 1.

PMID:
29387927
39.

Early Gastric Cancer: Clinical Behavior and Treatment Options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG).

Saragoni L, Scarpi E, Ravaioli A, Morgagni P, Roviello F, Vindigni C, Rausei S, Chiaravalli AM, Fumagalli U, Spaggiari P, Rosa F, Ricci R, Donini A, Giovenali P, Tomezzoli A, De Manzoni G.

Oncologist. 2018 Jul;23(7):852-858. doi: 10.1634/theoncologist.2017-0488. Epub 2018 Jan 31.

40.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassineti GL, Calistri D, Amadori D, Scarpi E.

Int J Mol Sci. 2018 Jan 20;19(1). pii: E307. doi: 10.3390/ijms19010307.

41.

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.

Conteduca V, Scarpi E, Caroli P, Salvi S, Lolli C, Burgio SL, Menna C, Schepisi G, Testoni S, Gurioli G, Paganelli G, Casadio V, Matteucci F, De Giorgi U.

Sci Rep. 2017 Nov 14;7(1):15541. doi: 10.1038/s41598-017-15928-y.

42.

High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.

Parisi E, Romeo A, Sarnelli A, Ghigi G, Bellia SR, Neri E, Micheletti S, Dipalma B, Arpa D, Furini G, Burgio MA, Genestreti G, Gurioli C, Sanna S, Bovolato P, Rea F, Storme G, Scarpi E, Arienti C, Tesei A, Polico R.

Cancer Radiother. 2017 Dec;21(8):766-773. doi: 10.1016/j.canrad.2017.05.007. Epub 2017 Nov 11.

PMID:
29132803
43.

Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6.

PMID:
29110067
44.

DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy.

Carloni S, Gallerani G, Tesei A, Scarpi E, Verdecchia GM, Virzì S, Fabbri F, Arienti C.

Onco Targets Ther. 2017 Sep 20;10:4657-4664. doi: 10.2147/OTT.S141117. eCollection 2017.

45.

NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.

Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.

Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.

46.

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.

Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D.

Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9.

47.
48.

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.

Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi A.

Int J Mol Sci. 2017 Jun 9;18(6). pii: E1240. doi: 10.3390/ijms18061240.

49.

Right- versus left-side metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy.

Ulivi P, Scarpi E, Valgiusti M, Casadei Gardini A, Marisi G, Calistri D, Ragazzini A, Chiadini E, Capelli L, Frassineti Giovanni L, Amadori D, Passardi A.

Ann Oncol. 2017 Jun;28 Suppl 3:iii8. doi: 10.1093/annonc/mdx263.019. No abstract available.

50.

Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT).

De Giorgi U, Richard S, Badoglio M, Kanfer E, Bourrhis JH, Nicolas-Virelizier E, Vettenranta K, Lioure B, Martin S, Dreger P, Schuler MK, Thomson K, Scarpi E, Rosti G, Selle F, Mangili G, Lanza F, Bregni M; Solid Tumours Working Party (STWP) of the EBMT.

Ann Oncol. 2017 Aug 1;28(8):1910-1916. doi: 10.1093/annonc/mdx259.

Supplemental Content

Loading ...
Support Center